femasys(US:FEMY)2025-11-14 21:09Financial Performance - Sales increased by $174,486, or 31.4%, to $729,394 for Q3 2025 compared to $554,908 for Q3 2024, primarily due to sales of FemBloc[8] - Net loss was $4,194,821, or ($0.10) per share for Q3 2025, compared to a net loss of $5,408,860, or ($0.24) per share for Q3 2024[8] - Cash and cash equivalents as of September 30, 2025, was approximately $4.6 million, with an accumulated deficit of approximately $141.9 million[8] Research and Development - Research and development expenses decreased by $921,219, or 40.0%, to $1,382,022 for Q3 2025 compared to $2,303,241 for Q3 2024, primarily due to commercialization of development products into inventory[8] Assets and Funding - Total assets increased to $16,290,153 as of September 30, 2025, compared to $12,445,002 as of December 31, 2024[10] - The company announced a definitive agreement for the issuance of $12 million in secured convertible notes, with total potential funding of $58 million if all warrants are exercised[4] Market Expansion - Regulatory approvals for the complete FemBloc System were secured in the U.K. and New Zealand, expanding access across Europe and the Asia-Pacific region[3] - The company received initial commercial orders from distribution partners in Spain and France, indicating early momentum in market expansion[3] - The company announced a partnership with Kebomed to commercialize FemBloc in France and the Benelux region[4] Operational Outlook - The company expects its current cash and cash equivalents will be sufficient to fund ongoing operations into September 2026[8]